BetterLife Pharma Files Final Prospectus for $100 Million Public Offering of Shares and Pre-Funded Warrants

11:23 AM EDT, 09/14/2026 (MT Newswires) -- BetterLife Pharma (BETR.CN) late Friday said it filed a final short form prospectus with securities regulators in British Columbia, Ontario and Alberta, in connection with a $100-million offering of shares and prefunded warrants announced last month. The company is offering of up to 555-million shares priced at CA$0.25 or CA$0.24999 per warrant for up to $100 million, with each warrant entitling the holder to buy a share. The offering must have a minimum raise of $80 million, the company said. BetterLife also granted the agents a 15% over-allotment option. . Proceeds will be used to conduct clinical trials, to initiate a post-Phase 2 registration study for cluster headache, and for working capital and other general corporate needs. Shares of the company were last seen up 5.9% to CA$0.36 on the Canadian Securities Exchange. Price: 0.36, Change: +0.02, Percent Change: +5.88